Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical

Allergan

Endo International

Florida has reached more than $878 million of settlements with CVS Health Corp and three drug companies to resolve claims over their roles in fueling an opioid epidemic in the third most populous U.S. state.

Florida reaches $878 million opioid settlements with CVS, Teva, others

CVS Health Corp said on Wednesday it had entered into an agreement with the state of Florida to resolve claims related toprescriptions for opioid medications for $484 million to be paid over a period of 18 years.

CVS Health reaches $484 million opioid settlement with Florida

CVS Health Corp. CVS, -3.11% announced Wednesday that it has settled opioid claims in Florida based on prescriptions filled in pharmacy locations in that state. Some of the claims date back more than 10 years.

CVS settles Florida opioid claims for $484 million

WOONSOCKET, R.I. , March 30, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) announced today that it has entered into an agreement with the State of Florida to resolve claims dating back more than a decade related to prescriptions for opioid medications that were filled at Florida CVS Pharmacy locations.

CVS Health Reaches Opioid Settlement Agreement with State of Florida

In the news release, CVS Health and Fresno Housing Collaborate to Address Affordable Housing Crisis and Provide Healthy Homes in Fresno County, issued 29-Mar-2022 by CVS Health over PR Newswire, we are advised by the company that the release has been revised. The complete, corrected release follows: CVS Health and Fresno Housing Collaborate to Address Affordable Housing Crisis and Provide Healthy Homes in Fresno County WOONSOCKET, R.I.

/C O R R E C T I O N -- CVS Health/

CVS's earnings could be dented by opioid litigation as well as changes affecting its pharmacy segment, Deutsche Bank says.

Deutsche Steps to the Sidelines on CVS Health

AmerisourceBergen

Moderna

These three fundamentally sound companies will protect both your vitals and your financial livelihood for years to come.

3 Healthcare Stocks With Healthy Fundamentals

Walgreens

Which pharmacy retailer should you put in your portfoliio?

Better Buy: Walgreens vs. CVS Health

Huntsman

Newell Brands

Webster Financial

It is hard to believe, but the first quarter will end in a week and many investors will be reviewing their portfolios and making changes for the second quarter and the rest of 2022.

5 Analyst ‘Strong Buy' Stocks Pay Dependable Dividends and May Be Big Q2 Winners

CVS Health Corp. ( CVS , Financial) is a potential value opportunity at current levels, from my perspective. Wall Street analysts are leaning to the bullish side as well.

Owning Shares of CVS Could Make Portfolios Healthier

CVS Health has encouraging fundamentals and recently resumed its dividend growth.

Could This Dividend Stock Be a Fit for Your Portfolio?

CVS Health (CVS) closed the most recent trading day at $107.11, moving +0.12% from the previous trading session.

CVS Health (CVS) Gains But Lags Market: What You Should Know

LEXINGTON, Ky.--(BUSINESS WIRE)-- #omnilife--OmniLife has been named a Finalist for the 2022 Innovation Challenge in Kidney Disease by Lyfebulb and CVS Kidney Care®.

OmniLife Named a Finalist for the 2022 Innovation Challenge in Kidney Disease by Lyfebulb and CVS Kidney Care®

CVS Health Corporation (CVS) Presents at 2022 Barclays Healthcare Conference (Transcript)

NEW YORK and WOONSOCKET, R.I. , March 15, 2022 /PRNewswire/ -- Lyfebulb and CVS Kidney Care®, a CVS Health® (NYSE:CVS) company, are pleased to announce 10 finalists for the 2022 Innovation Challenge: Accelerating Innovations in Kidney Disease to Improve Health Equity and Outcomes.

Lyfebulb and CVS Kidney Care® Announce Finalists for 2022 Innovation Challenge in Kidney Disease

Atlanta Braves Holdings Inc

Bristol-Myers

Comcast

Paramount Global

By now you've gotten the memo that it's time to own value stocks, since value beats growth when consumer prices and interest rates rise.

Value investing is back: Here's how to dodge the losers and spot the winners — with five stocks to consider

Automatic Data Processing

Bath and Body Works

Hologic

Parker-Hannifin

Ralph Lauren

Tapestry

The number of companies raising guidance in 2022 has been slower than usual. Here are seven S&P 500 stocks that have upped guidance.

7 S&P 500 Stocks That Have Raised Their Guidance in 2022

At least two female CVS employees alleged a New Jersey-based regional store manager touched them inappropriately or harassed them at work, WSJ says.

CVS CEO Karen Lynch fires executives after internal sexual harassment investigation, report says

CVS Health Corp. CVS, +0.15% Chief Executive Karen Lynch has removed several executives, following the health care services and drug store chain's internal probe into how sexual harassment complaints were handled, according to a report in The Wall Street Journal. Citing people familiar with the matter, the WSJ report said CVS's investigation came after Lynch became aware of complaints made by two female employees who alleged that they were either harassed or inappropriately touched while at work by a New Jersey-based regional store manager who oversaw hundreds of stores.

CVS ousts several executives following investigation into handling of sexual harassment complaints--WSJ

CVS Health (CVS) reported earnings 30 days ago. What's next for the stock?

Why Is CVS Health (CVS) Down 1.2% Since Last Earnings Report?

You don't need to invest in the top tech stocks to get exposure to the metaverse.

1 Surprising Stock That's Also Looking to Get Into the Metaverse

WOONSOCKET, R.I., March 10, 2022 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced that David W.

CVS Health Announces Changes to Board of Directors

WOONSOCKET, R.I., March 9, 2022 /PRNewswire/ -- CVS Health (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of fifty-five cents ($0.55) per share on the Common Stock of the Corporation.

CVS Health Announces Quarterly Dividend

We believe that CVS Health stock currently appears to be an attractive pick over its peer Target stock due to its comparatively lower valuation and better prospects. CVS trades at about 0.5x trailing revenues, compared to 0.9x for TGT.

News for CVS Health Stock (CVS)